公众号 / 文章复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克血流动力学管理个体化的呼吁

A plea for personalization of the hemodynamic management of septic shock.
PubMed 文献 · Crit Care · 2022-12-01
一句话结论脓毒性休克血流动力学管理应按救治、优化、稳定、降阶梯四阶段个体化监测与治疗,去甲肾上腺素推荐为一线升压药。

本文为综述,指出指南虽提供专家指导但留有个体化空间。血流动力学监测取决于休克演变阶段:救治阶段用动脉压、乳酸、皮肤花斑和毛细血管再充盈时间识别病因与严重度,低舒张压可触发升压药启动,超声可识别显著心功能障碍;优化阶段用超声联合中心/混合静脉血氧饱和度、乳酸、二氧化碳静脉-动脉梯度评估组织灌注,最严重患者可考虑经肺热稀释和肺动脉导管。液体治疗随阶段变化:救治阶段可宽松补液,优化阶段评估液体反应性,稳定阶段最小化补液,降阶梯阶段在保证组织灌注下安全撤液。去甲肾上腺素推荐为一线升压药,部分患者可能优选血管加压素;正性肌力药首选小剂量多巴酚丁胺,二线加依诺昔酮或米力农,无效时替换或加用左西孟旦。

要点

  • 去甲肾上腺素推荐为一线升压药,部分患者可能优选血管加压素。
  • 救治阶段监测包括动脉压、乳酸、皮肤花斑和毛细血管再充盈时间;低舒张压可能触发升压药启动。
  • 优化阶段应继续超声监测,并完成中心或混合静脉血氧饱和度、乳酸、二氧化碳静脉-动脉梯度评估组织灌注。
  • 液体治疗随阶段变化:救治阶段可宽松补液,优化阶段评估液体反应性,稳定阶段最小化补液,降阶梯阶段在保证组织灌注下安全撤液。
  • 正性肌力药建议先试小剂量多巴酚丁胺,二线加依诺昔酮或米力农,无效时替换或加用左西孟旦。

适用人群与场景

  • 脓毒性休克患者,按休克演变阶段分为救治、优化、稳定和降阶梯四个阶段进行管理。

处置流程与药物剂量

  • 救治阶段:监测动脉压和乳酸,结合临床检查尤其皮肤花斑和毛细血管再充盈时间,以识别休克病因和严重度;低舒张压可能触发升压药启动;超声可能有助于识别显著心功能障碍。
  • 优化阶段:应继续超声心动图监测,并完成组织灌注评估,包括中心或混合静脉血氧饱和度、乳酸和二氧化碳静脉-动脉梯度;最严重患者应考虑经肺热稀释和肺动脉导管。
  • 液体治疗:救治阶段可宽松补液;优化阶段应评估液体反应性;稳定阶段应最小化补液;降阶梯阶段在确保组织灌注得以保留的情况下可安全撤液。
  • 升压药:去甲肾上腺素推荐为一线升压药,部分患者可能优选血管加压素;血清肾素和血管紧张素I/II比值可能识别最受益于血管紧张素II的患者;升压药治疗应个体化,基于临床评估和血流测量以避免过度血管收缩。
  • 正性肌力药:对心脏收缩力下降伴组织灌注受损的患者应考虑正性肌力药;基于药理学特性,建议首先试用有限剂量的多巴酚丁胺,二线加用依诺昔酮或米力农,无效时替换或加用左西孟旦。
  • 辅助治疗:目前建议接受高剂量升压药的患者使用氢化可的松;未来可能通过分析特定细胞因子或特定转录组内型来识别对糖皮质激素有反应的患者。

研究设计与关键结果

  • 本文为综述,指出指南虽提供专家指导但留有个体化空间,血流动力学监测取决于休克演变阶段(救治、优化、稳定、降阶梯),液体治疗和升压药、正性肌力药选择也应随阶段和患者个体化。

对床旁实践的改变

  • 作者认为,尽管休克管理适用一些通用规则,但血流动力学监测和支持应考虑个体化方法。
  • 去甲肾上腺素推荐为一线升压药,部分患者可能优选血管加压素。
  • 正性肌力药建议首先试用有限剂量的多巴酚丁胺,二线加用依诺昔酮或米力农,无效时替换或加用左西孟旦。
  • 目前建议接受高剂量升压药的患者使用氢化可的松。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「证据类型、等级与局限」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Although guidelines provide excellent expert guidance for managing patients with septic shock, they leave room for personalization according to patients' condition. Hemodynamic monitoring depends on the evolution phase: salvage, optimization, stabilization, and de-escalation. Initially during the salvage phase, monitoring to identify shock etiology and severity should include arterial pressure and lactate measurements together with clinical examination, particularly skin mottling and capillary refill time. Low diastolic blood pressure may trigger vasopressor initiation. At this stage, echocardiography may be useful to identify significant cardiac dysfunction. During the optimization phase, echocardiographic monitoring should be pursued and completed by the assessment of tissue perfusion through central or mixed-venous oxygen saturation, lactate, and carbon dioxide veno-arterial gradient. Transpulmonary thermodilution and the pulmonary artery catheter should be considered in the most severe patients. Fluid therapy also depends on shock phases. While administered liberally during the resuscitation phase, fluid responsiveness should be assessed during the optimization phase. During stabilization, fluid infusion should be minimized. In the de-escalation phase, safe fluid withdrawal could be achieved by ensuring tissue perfusion is preserved. Norepinephrine is recommended as first-line vasopressor therapy, while vasopressin may be preferred in some patients. Essential questions remain regarding optimal vasopressor selection, combination therapy, and the most effective and safest escalation. Serum renin and the angiotensin I/II ratio may identify patients who benefit most from angiotensin II. The optimal therapeutic strategy for shock requiring high-dose vasopressors is scant. In all cases, vasopressor therapy should be individualized, based on clinical evaluation and blood flow measurements to avoid excessive vasoconstriction. Inotropes should be considered in patients with decreased cardiac contractility associated with impaired tissue perfusion. Based on pharmacologic properties, we suggest as the first test a limited dose of dobutamine, to add enoximone or milrinone in the second line and substitute or add levosimendan if inefficient. Regarding adjunctive therapies, while hydrocortisone is nowadays advised in patients receiving high doses of vasopressors, patients responding to corticosteroids may be identified in the future by the analysis of selected cytokines or specific transcriptomic endotypes. To conclude, although some general rules apply for shock management, a personalized approach should be considered for hemodynamic monitoring and support.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. De Backer D, Cecconi M, Chew MS, et al. A plea for personalization of the hemodynamic management of septic shock. Crit Care. 2022. PMID: 36457089. doi:10.1186/s13054-022-04255-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。